Clinical trials: Early Psychosis, open to volunteers
Schizophrenia and Related Disorders, Early Treatment-Resistance
The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
Schizophrenia (SZ) affects approximately 4.5 million people across the European Union (EU) and is associated with annual healthcare and societal costs of 29 billion Euros.
- Trial name
- INTENSIFY SZ (NCT05958875)
- Testing
- Clozapine, Second-line Antipsychotics (treatment as usual)
- Where
- 13 sites in Austria, Germany and 3 more
- Volunteers
- 418 people
- Sponsor
- Dr. Inge Winter
Early Psychosis, Schizophrenia Prodromal
Perception and Integration of Sensory Information in the Early Stages of Psychosis
The goal of this observational study is to investigate the early sensory system in clinical high risk (CHR), first episode psychosis (FEP) individuals and heathly controls.
- Trial name
- PRIOR-ePSY (NCT07446569)
- Testing
- behavioral tasks, Electroretinography, Comprehensive Assessment of At Risk Mental States (CAARMS)
- Where
- 4 sites in France
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Centre Psychothérapique de Nancy
Prodromal Schizophrenia
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms of patients with schizophrenia. Whether treatment of an NMDA-enhancing agent can benefit the treatment of prodromal schizophrenia…
- Trial name
- NCT05052853
- Testing
- NMDAE
- Where
- Taiwan
- Volunteers
- 48 people
- Sponsor
- China Medical University Hospital
Clinical High Risk for Psychosis (CHR), Suicidal Ideation
Developing a Recovery-Oriented Suicide Prevention Program for Young People at Clinical High Risk for Psychosis
Young people at clinical high risk for psychosis are more likely to experience suicide thoughts than the general population, but there are few suicide prevention programs designed specifically for them.
- Conditions
- Clinical High Risk for Psychosis (CHR), Suicidal Ideation, Psychosis, Suicidal Behavior
- Trial name
- NCT07756567
- Testing
- Suicide Prevention Intervention, Standard Care (in control arm)
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- University of California, San Diego
Psychosis, Cannabis Use Disorder
Testing the Efficacy of the Cannabis Clinic for Patients With Psychosis (CCP) Intervention for Cannabis Use Reduction/Cessation in Patients With First Episode Psychosis (FEP)
People suffering from psychosis who use cannabis experience more relapses, long and compulsory admissions, with huge costs to the individual, families and health services.
- Conditions
- Psychosis, Cannabis Use Disorder, First Episode Psychosis (FEP)
- Trial name
- CCP RCT (NCT07245212)
- Testing
- CCP Intervention
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- King's College London
Violence Risk, Early Psychosis
BRAVE Program to Improve Safety and Reduce Violence Risk in Early Psychosis
This study evaluates the feasibility and acceptability of BRAVE, a manualized cognitive behavioral therapy (CBT)-based intervention designed to address dynamic risk factors for violence among young adults with early psychosis.
- Trial name
- BRAVE (NCT07417904)
- Testing
- BRAVE (Behavioral Response Against Violence Engagement), Treatment As Usual (TAU)
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Howard University
Early Psychosis, Psychosis
State Representation in Early Psychosis 2
This observational study will examine behavioral and electroencephalography measures related to state representation in individuals with early psychosis and healthy control participants.
- Conditions
- Early Psychosis, Psychosis, Schizophrenia, Bipolar Disorder With Psychosis
- Trial name
- STEP2 (NCT07834203)
- Where
- 2 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Delusional Disorder, Brief Psychotic Disorder
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone.
- Conditions
- Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
- Trial name
- FEEL-GOOD (NCT07645443)
- Testing
- FEEL GOOD, Treatment as Usual (TAU)
- Where
- 8 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Stephanie Mehl
Child, Parents
The VIA Family 2.0 - a Family Based Intervention for Families with Parental Mental Illness
VIA Family 2.0 - a Family Based Intervention for families with parental mental illness Background: Children born to parents with mental illness have consistently been shown to have increased risks for a range of negative life…
- Conditions
- Child, Parents, Mental Disorder, Child of Impaired Parents
- Trial name
- NCT06312410
- Testing
- VIA Family 2.0
- Where
- Denmark
- Volunteers
- 1,452 people
- Sponsor
- Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Psychosis, Schizophrenia Disorder
Cognitive Strategies in Early Psychosis 2
The goal of this clinical trial is to learn more about decision making in psychosis spectrum disorders, like schizophrenia. Participants will be people who have had symptoms of a psychosis spectrum disorder start within the last…
- Conditions
- Psychosis, Schizophrenia Disorder, Schizoaffective Disorder, Major Depressive Disorder With Psychotic Features
- Trial name
- COSTEP 2 (NCT07263022)
- Testing
- Modafinil, D-serine solution
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Minnesota
Schizophrenia
An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients
This is an open label study of the treatment satisfaction, efficacy and tolerability of xanomeline/ trospium in a population of 172 participants diagnosed with schizophrenia in the early phase of illness.
- Trial name
- NCT06923891
- Testing
- Xanomeline/Trospium
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Vanguard Research Group
Psychosis, Anxiety
Pilot Study of Sensor-Informed Smartphone-based Mental Health Interventions for Mood in Early Psychosis
The aim of this trial is to evaluate the feasibility and preliminary efficacy of using passive smartphone sensors to detect moments of heightened negative mood and inform the timing of brief mental health interventions, such as…
- Conditions
- Psychosis, Anxiety, Depression, Rumination
- Trial name
- NCT07503093
- Testing
- Smartphone-based Mindfulness Exercise, Smartphone-based Psychoeducation, Neutral Control Message
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mclean Hospital
Psychotic Episode
Impact of an Early Identification Program for First-Episode Psychosis on the Duration of Untreated Psychosis
The First-Episode Psychosis (FPE) is a severe disorder that can include delusions, cognitive disorders and suicidal behavior. In the majority of cases (more than 80%) it evolves into schizophrenia.
- Trial name
- PRESTO (NCT05813457)
- Testing
- PRESTO Early Identification Program
- Where
- 6 sites in France
- Volunteers
- 416 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Suicide, Mental Health Stigma
Reducing Stigma - A Treatment for Early Psychosis to Prevent Suicide
A mental health program, called RESTEPS, will be developed for patients with early psychosis being treated in outpatient mental health centers, focusing on reducing suicide risk by targeting mental health stigma and social…
- Trial name
- AFSP RESTEPS (NCT07898631)
- Testing
- RESTEPS
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Butler Hospital
First Episode Psychosis (FEP), Psychosis
Early Psychosis: Investigating Cognition
The project aims to explore changes in brain chemistry in individuals who have recently experienced psychosis. Recent research suggests that chemicals in the brain, specifically one called glutamate, may behave differently in…
- Trial name
- EPIC (NCT07196423)
- Testing
- Transcranial direct current stimulation (tDCS), Magnetic Resonance Imaging
- Where
- United Kingdom
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Clinical High Risk, Early Psychosis
Digital Strategies to Advance Help-Seeking - Aim 3
This proposal aims to establish a Digital Laboratory focused on advancing help-seeking and expediting treatment initiation in youth ages 12-29 who are at Clinical High-Risk (CHR) for developing psychosis.
- Conditions
- Clinical High Risk, Early Psychosis, First Episode Psychosis
- Trial name
- NCT06774417
- Testing
- Digital nudge
- Where
- United States
- Volunteers
- 25,000 people
- Sponsor
- Columbia University
Sleep, Physical Activity
On Track for Wellness (OTW) Stepped Wedge Cluster Randomized Trial
This study will evaluate a program called On Track for Wellness (OTW) which is being adopted by the Illinois Department of Human Services' Division of Behavioral Health \& Recovery (DBHR) for use in all state-funded early…
- Conditions
- Sleep, Physical Activity, First Episode Psychosis
- Trial name
- OTW (NCT07387705)
- Testing
- On Track for Wellness
- Where
- United States
- Volunteers
- 365 people
- Sponsor
- University of Illinois Chicago
Severe Mental Illness, Bipolar Disorder
A Mobile App to Support Mood, Daily Routines and Medication Adherence in Adults With Severe Mental Illness
The goal of this clinical trial is to learn whether MoodSync, a mobile application for patients and their family caregivers, improves mood stability, medication adherence, daily functioning and early detection of relapse warning…
- Conditions
- Severe Mental Illness, Bipolar Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- MoodSync (NCT07879131)
- Testing
- MoodSync, Standard care
- Where
- Bahrain
- Volunteers
- 60 people
- Sponsor
- Alexandria University
Device Adherence
Effectiveness of a Digital Platform in Engagement and Prognosis of Patients in an Early Intervention Pychosis Programme
This is a randomised, prospective, controlled trial in which one group (experimental group; GE) receives access to the PIPPEP (Intervention Programme for Early Psychosis) platform in addition to the treatment as usual (TAU) in…
- Trial name
- NCT06556251
- Testing
- PIPPEP App
- Where
- Spain
- Volunteers
- 128 people
- Sponsor
- Fundació Sant Joan de Déu
Family Members, Implementation
FAmily Engagement Strategy for Coordinated Specialty Care
Family members/support persons' engagement in mental health services has been linked to reduced burden and stress and improves engagement and outcomes in individuals in the early stages of psychosis.
- Trial name
- FAMES (NCT06945055)
- Testing
- FAMES, Control
- Where
- 4 sites in United States
- Volunteers
- 900 people
- Sponsor
- Washington State University